Retrospective Analysis of Retroperitoneal-Abdominal-Pelvic Ganglioneuromas
Sangkyu Noh(UC San Diego Health System), Ynez Howlett-Jansen(Peter MacCallum Cancer Centre), Gausihi Sivarajah(Royal Marsden Hospital), Andraž Perhavec(The University of Texas MD Anderson Cancer Center), Hayden Snow(Peter MacCallum Cancer Centre), Chenghua Luo(Peking University), Carol J. Swallow(University Health Network), Teresa S. Kim(University of Washington), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), Eran Nizri(Tel Aviv University), Wendy Johnston(University of Toronto), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Shintaro Iwata(National Cancer Centre Japan), Dagmar Adámková Krákorová(Masaryk Memorial Cancer Institute), Federico Sicoli(Humanitas University), Winta T. Mehtsun(UC San Diego Health System), Max Almond(Queen Elizabeth Hospital Birmingham), Francesco Tolomeo(Candiolo Cancer Institute), Chandrajit P. Raut(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Suguru Fukushima(Western University of Health Sciences), Daphne Hompes, Maria Krotewicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Caroline Evenden(University Hospitals Birmingham NHS Foundation Trust), Fabio Tirotta(University Hospitals Birmingham NHS Foundation Trust), Mireia Solans Solerdecoll(Universitat Autònoma de Barcelona), Nikolaos Vassos(European University Cyprus), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bruno Vincenzi(Campus Bio Medico University Hospital), Mark Fairweather(Brigham and Women's Hospital), Emily Z. Keung(The University of Texas MD Anderson Cancer Center), Adriana C. Gamboa(Emory University), Jeffrey M. Farma(Fox Chase Cancer Center), Stefano Piero Bernardo Cioffi(Fondazione IRCCS Istituto Nazionale dei Tumori), Sergio Quildrian(Universidad de Buenos Aires), Davide Biasoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Christina L. Roland(The University of Texas MD Anderson Cancer Center), Jun Chen(Peking University), Laura Nguyen(Ottawa Hospital), Marleen Renard, Stephanie H. Greco(Rutgers, The State University of New Jersey), Elisabetta Pennacchioli(European Institute of Oncology), Christoph O. Ryser(University of Bern), José Antonio González López(Universitat Autònoma de Barcelona), Attila Kollár(University Hospital of Bern)
Cited by 13
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k